Company news

Esperion Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

December 12, 2023

Esperion Reports Third Quarter 2023 Financial Results

November 6, 2023

Esperion to Report Third Quarter 2023 Financial Results on November 7

October 23, 2023

Esperion Reports Second Quarter 2023 Financial Results

July 31, 2023

Esperion to Report Second Quarter 2023 Financial Results on August 1

July 16, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

June 27, 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

May 31, 2023

Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders

May 24, 2023

Esperion Reports First Quarter 2023 Financial Results

May 8, 2023

Esperion to Report First Quarter 2023 Financial Results May 9, 2023

April 24, 2023

Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC

April 18, 2023

Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 19, 2023

Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

February 20, 2023

Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC

February 19, 2023

Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023

February 6, 2023

Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results

January 7, 2023

Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

December 6, 2022

Esperion Appoints Ben Halladay Chief Financial Officer

November 15, 2022

Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update

October 31, 2022

Esperion to Report Third Quarter 2022 Financial Results November 1, 2022

October 16, 2022

Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

August 25, 2022

Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update

August 1, 2022

Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management

July 24, 2022

Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors

May 31, 2022

Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions

May 30, 2022

Esperion Reports First Quarter 2022 Financial Results and Provides Company Update

May 2, 2022

Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology

May 1, 2022

Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors

April 27, 2022

Esperion to Report First Quarter 2022 Financial Results May 3, 2022

April 18, 2022

Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology

April 12, 2022

Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo

April 2, 2022

Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

February 21, 2022

Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022

February 7, 2022

Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update

January 10, 2022

Esperion Appoints Benjamin O. Looker as General Counsel

January 3, 2022

Esperion Announces Closing of $225 Million Public Offering

December 6, 2021

Esperion Announces Proposed Public Offering

December 1, 2021

Esperion Announces Pricing of $225 Million Public Offering

December 1, 2021

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update

November 1, 2021

Esperion Announces the Appointment of Seth H.Z. Fischer to its Board of Directors

October 31, 2021

ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock

October 24, 2021

ESPERION Announces Plan for Transformative Long-Term Growth

October 17, 2021

Esperion to Report Third Quarter 2021 Financial Results November 2, 2021

October 11, 2021

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update

August 2, 2021

Esperion to Report Second Quarter 2021 Financial Results August 3, 2021

July 12, 2021

ESPERION Appoints JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer

June 27, 2021

ESPERION Appoints Sheldon Koenig as President and CEO

May 16, 2021

ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update

May 3, 2021

Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal

April 26, 2021

Esperion to Report First Quarter 2021 Financial Results May 4, 2021

April 11, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.